Lung cancer serum biomarker discovery using label-free liquid chromatography-tandem mass spectrometry

Journal of Thoracic Oncology

Volumn 6, Issue 4, 2011, Pages 725-734

  Zeng, Xuemei ^a   Hood, Brian L ^a,d   Zhao, Ting ^a,b   Conrads, Thomas P ^a,b,d   Sun, Mai ^a   Gopalakrishnan, Vanathi ^c   Grover, Himanshu ^c   Day, Roger S ^c   Weissfeld, Joel L ^a,b   Wilson, David O ^c   Siegfried, Jill M ^a,b   Bigbee, William L ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c Department of Biomedical Informatics ^*  (United States)

^d BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

Author keywords

liquid chromatographymass spectrometry mass spectrometry; Lung cancer; Serum biomarkers

Indexed keywords

BIOLOGICAL MARKER;

ADULT; AGED; ANTIBODY AFFINITY; ARTICLE; BLOOD SAMPLING; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; TANDEM MASS SPECTROMETRY;

EID: 79953027129     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31820c312e     Document Type: Article

References (24)

1. Okada M, Nishio W, Sakamoto T, et al. Effect of tumor size on prognosis in patients with non-small cell lung cancer: the role of segmentectomy as a type of lesser resection. J Thorac Cardiovasc Surg 2005;129:87-93. (Pubitemid 40038100)
2. Smith RA, Cokkinides V, Brooks D, et al. Cancer screening in the United States, 2010: a reviews of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin 2010;60: 99-119.
3. Kaneko M, Eguchi K, Ohmatsu H, et al. Peripheral lung cancer: screening and detection with low-dose spiral CT versus radiography. Radiology 1996;201:798-802.
4. Welch HG, Woloshin S, Schwartz LM, et al. Overstating the evidence for lung cancer screening: the International Early Lung Cancer Action Program (I-ELCAP) study. Arch Intern Med 2007;167:2289-2295. (Pubitemid 350179522)
5. Wilson DO, Weissfeld JL, Fuhrman CR, et al. The Pittsburgh Lung Screening Study (PLuSS): outcomes within 3 years of a first computed tomography scan. Am JRespir Crit Care Med 2008;178:956-961.
6. Buccheri G, Torchio P, Ferrigno D. Clinical equivalence of two cyto-keratin markers in non-small cell lung cancer: a study of tissue poly-peptide antigen and cytokeratin 19 fragments. Chest 2003;124:622-632. (Pubitemid 37000143)
7. Pastor A, Menéndez R, Cremades MJ, et al. Diagnostic value of SCC, CEA and CYFRA 21.1 in lung cancer: a Bayesian analysis. Eur Respir J 1997;10:603-609. (Pubitemid 27112576)
8. Rapellino M, Niklinski J, Pecchio F, et al. CYFRA 21-1 as a tumour marker for bronchogenic carcinoma. Eur Respir J 1995;8:407-410.
9. Okano T, Kondo T, Kakisaka T, et al. Plasma proteomics of lung cancer by a linkage of multi-dimensional liquid chromatography and two-dimensional difference gel electrophoresis. Proteomics 2006;6:3938-3948. (Pubitemid 44065171)
10. Heo SH, Lee SJ, Ryoo HM, et al. Identification of putative serum glycoprotein biomarkers for human lung adenocarcinoma by multilectin affinity chromatography and LC-MS/MS. Proteomics 2007;7:4292-4302.
11. Liu H, Sadygov RG, Yates JR 3rd. A model for random sampling and estimation of relative protein abundance in shotgun proteomics. Anal Chem 2004;76:4193-4201. (Pubitemid 38943698)
12. Old WM, Meyer-Arendt K, Aveline-Wolf L, et al. Comparison of label-free methods for quantifying human proteins by shotgun proteom-ics. Mol Cell Proteomics 2005;4:1487-1502. (Pubitemid 41555475)
13. Gardner W, Mulvey EP, Shaw EC Regression analyses of counts and rates: Poisson, overdispersed Poisson, and negative binomial models. Psychol Bull 1995;118:392-404.
14. Anderson L, Hunter CL. Quantitative mass spectrometric multiple reac-tion monitoring assays for major plasma proteins. Mol Cell Proteomics 2006;5:573-588.
15. Kuzyk MA, Smith D, Yang J, et al. Multiple reaction monitoring-based, multiplexed, absolute quantitation of 45 proteins in human plasma. Mol Cell Proteomics 2009;8:1860-1877.
16. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Statist Soc B 1995;57:289-300.
17. Ingenuity® Systems. The Networks and Functional Analyses were Gen-erated through the Use of Ingenuity Pathways Analysis. Available at: www.ingenuity.com. Accessed June 22, 2010.
18. Chourey K, Thompson MR, Shah M, et al. Comparative temporal proteomics of a response regulator (SO2426)-deficient strain and wild-type Shewanella oneidensis MR-1 during chromate transformation. J Proteome Res 2009;8:59-71.
19. Sprung RW Jr, Brock JW, Tanksley JP, et al. Equivalence of protein inventories obtained from formalin-fixed paraffin-embedded and frozen tissue in multidimensional liquid chromatography-tandem mass spec-trometry shotgun proteomic analysis. Mol Cell Proteomics 2009;8: 1988-1998.
20. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140:883-899.
21. Ginsberg MS, Grewal RK, Heelan RT. Lung cancer. Radiol Clin North Am 2007;45:21-43. (Pubitemid 44854042)
22. Hou J, Aerts J, den Hamer B, et al. Gene expression-based classification of non-small cell lung carcinomas and survival prediction. PLoS One 2010;5:e10312.
23. Landi MT, Zhao Y, Rotunno M, et al. MicroRNA expression differen-tiates histology and predicts survival of lung cancer. Clin Cancer Res 2010;16:430-441.
24. Kapoor D, Jones TH. Smoking and hormones in health and endocrine disorders. Eur J Endocrinol 2005;152:491-499. (Pubitemid 40575793)